APELLIS PHARMACEUTICALS INC (APLS)
US03753U1060 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 351.19M | 551.80M | 640.20M | 565.80M | 352.00M | |||
| Marketable Securities | N/A | 0.00 | 60.40M | 311.90M | N/A | |||
| Receivables | 224.50M | 29.20M | 10.10M | N/A | N/A | |||
| Inventories | 146.36M | 85.70M | 16.30M | N/A | N/A | |||
| Other Current Assets | 44.29M | 52.90M | 97.10M | 39.50M | 21.10M | |||
| Total Current Assets | 766.33M | 719.50M | 824.00M | 917.20M | 373.10M | |||
| Non-Current Assets | ||||||||
| PPE Net | 21.09M | 24.90M | 26.10M | 24.50M | 15.80M | |||
| Other Non-Current Assets | 1.31M | 15.80M | 31.60M | 18.90M | 400.00K | |||
| Total Non-Current Assets | 22.40M | 40.70M | 57.80M | 43.40M | 16.10M | |||
| TOTAL ASSETS | 788.73M | 760.20M | 881.80M | 960.60M | 389.20M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 75.83M | 29.50M | 7.60M | 4.20M | N/A | |||
| Accrued Expenses | 134.25M | 100.80M | 107.40M | 115.60M | 57.40M | |||
| Accounts Payable | 37.52M | 37.30M | 16.90M | 8.50M | 8.40M | |||
| Total Current Liabilities | 247.59M | 167.60M | 131.80M | 128.30M | 65.80M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 332.85M | 408.40M | 534.20M | 358.80M | 142.60M | |||
| Other Non-Current Liabilities | 13.77M | 14.40M | 17.10M | 268.90M | 146.70M | |||
| Total Non-Current Liabilities | 346.62M | 422.70M | 551.30M | 627.70M | 289.20M | |||
| TOTAL LIABILITIES | 594.21M | 590.30M | 683.10M | 756.00M | 355.00M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -2.84B | -2.31B | -1.66B | -926.30M | -581.50M | |||
| Additional Paid In Capital | 3.04B | 2.48B | 1.86B | 1.13B | 615.80M | |||
| Common Shares | 12.00K | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -2.57M | -2.50M | -2.10M | -100.00K | -200.00K | |||
| Shares Outstanding | 119.56M | 110.80M | 97.50M | 76.10M | 63.90M | |||
| Tangible Book Value per Share | 1.63 | 1.53 | 2.04 | 2.69 | 0.54 | |||
| Total Shareholders' Equity | 194.52M | 169.90M | 198.70M | 204.60M | 34.20M | |||
| TOTAL LIABILITIES AND EQUITY | 788.73M | 760.20M | 881.80M | 960.60M | 389.20M | |||
| Statistics | ||||||||
| Debt/Equity | 1.71 | 2.40 | 2.69 | 1.75 | 4.17 | |||
| Current Ratio | 3.10 | 4.29 | 6.25 | 7.15 | 5.67 | |||
| Return On Assets (ROA) | -67.02% | -85.79% | -84.65% | -35.90% | -78.29% | |||
| Return On Equity (ROE) | -271.76% | -383.87% | -375.64% | -168.57% | -890.94% | |||
All data in USD